Zimmer Biomet Holdings Inc (ZBH) Insider Bryan C. Hanson Acquires 25,077 Shares

Zimmer Biomet Holdings Inc (NYSE:ZBH) insider Bryan C. Hanson acquired 25,077 shares of Zimmer Biomet stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $119.68 per share, with a total value of $3,001,215.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $118.68 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. The firm has a market cap of $24,030.00, a price-to-earnings ratio of 45.13, a price-to-earnings-growth ratio of 2.12 and a beta of 1.08. Zimmer Biomet Holdings Inc has a one year low of $108.03 and a one year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the consensus estimate of $2.10. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.14 earnings per share. equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is presently 36.50%.

A number of research analysts have recently commented on ZBH shares. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target for the company in a research report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and boosted their price target for the company from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity restated a “hold” rating and set a $132.00 price target on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and set a $142.00 price target on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $141.67.

A number of institutional investors have recently bought and sold shares of the business. Bank of Nova Scotia Trust Co. bought a new position in shares of Zimmer Biomet during the third quarter valued at about $112,000. FNY Managed Accounts LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at about $117,000. Cerebellum GP LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $133,000. We Are One Seven LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $137,000. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of Zimmer Biomet during the third quarter valued at about $140,000. 88.18% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings Inc (ZBH) Insider Bryan C. Hanson Acquires 25,077 Shares” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/22/zimmer-biomet-holdings-inc-zbh-insider-bryan-c-hanson-acquires-25077-shares.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply